Carmell Corporation (CTCX)
- Previous Close
0.3490 - Open
0.3470 - Bid 0.3263 x 100
- Ask 0.3341 x 100
- Day's Range
0.3127 - 0.3500 - 52 Week Range
0.2900 - 4.3130 - Volume
387,035 - Avg. Volume
4,623,364 - Market Cap (intraday)
6.945M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
www.carmellcosmetics.com9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CTCX
View MorePerformance Overview: CTCX
Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTCX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTCX
View MoreValuation Measures
Market Cap
6.94M
Enterprise Value
5.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
563.70
Price/Book (mrq)
--
Enterprise Value/Revenue
450.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-84.64%
Return on Equity (ttm)
--
Revenue (ttm)
12.32k
Net Income Avi to Common (ttm)
-15.97M
Diluted EPS (ttm)
-0.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
2.2M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.49M